Click on the tabs above by lung cancer type to view active trials.
Protocol # | Sponsor | Protocol Title |
---|---|---|
NCT02296125 | AstraZeneca D5160C00007, 2014-002694-11, U1111-1160-2242 | A Phase III, Double-blind, Randomized Study to Assess the Safety and Efficacy of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer |
NCT02367781 | Hoffmann-La Roche GO29537, 2014-003206-32 | A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer |
NCT02367794 | Hoffmann-La Roche GO29437 | A Phase III, Open-label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of MPDL3208A (Anti-PDL-1 Antibody) in Combination with Carboplatin + Paclitaxel or MPDL3208A in Combination with Carboplatin + Nab-paclitaxel Versus Carboplatin + Nab-paclitaxel in Chemotherapy-naive Patients with Stage IV Squamous Non-small Cell Lung Cancer |
NCT02125461 | AstraZeneca D4191C00001 | A Phase III Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients with Stage III Unresectable Non-Small Cell Lung Cancer |
NCT02477826 | Bristol-Myers Squibb CA209-227, 2014-003630-23 | An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, Versus Platinum Doublet Chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) |
Protocol # | Sponsor | Protocol Title |
---|---|---|
NCT0220757 | CytRx | A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy |